IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

Relapse to anti-HER2 monoclonal antibody (mAb) therapies, such as trastuzumab in HER2(+) breast cancer (BC), is associated with residual disease progression due to resistance to therapy. Here, we identify interferon-γ inducible protein 16 (IFI16)-dependent STING signaling as a significant determinan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Li-Teng, Lee, Wee Chyan, Ma, Shijun, Oguz, Gokce, Niu, Zhitong, Bao, Yi, Yusuf, Mubaraka, Lee, Puay Leng, Goh, Jian Yuan, Wang, Panpan, Yong, Kylie Su Mei, Chen, Qingfeng, Wang, Wenyu, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351446/
https://www.ncbi.nlm.nih.gov/pubmed/35878022
http://dx.doi.org/10.1073/pnas.2201376119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351446/
https://www.ncbi.nlm.nih.gov/pubmed/35878022
http://dx.doi.org/10.1073/pnas.2201376119

Ejemplares similares